A retrospective study investigated the efficacy of this combination therapy, and found that PEGV in combination with cabergoline normalized IGF-1 levels in 4 out of 14 acromegaly patients (28%) and decreased IGF-1 levels in 9 out of 14 patients (64%) ( 38 ). The gene discussed is IGF1; the disease is acromegaly.